Immunogen study achieves primary goal of shrinking tumors in patients with ovarian cancer
Based on the study outcome, the company plans to submit the treatment for accelerated approval with the FDA in early 2022.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
All Coverage
advertisement
